EGFR‐targeted therapies, such as cetuximab, competitively block the binding of endogenous EGF ligand to the EGFR, which blocks the receptor‐dependent signal transduction pathways for the growth and survival of tumor cells [15]. The gene discussed is EGFR; the disease is neoplasm.